Abstract |
Nuclear medicine has been implicated in the diagnosis and treatment of endocrine disorders for several decades. With recent development of PET tracers, functional imaging now plays a major role in endocrine tumors enabling with high performance to their localization, characterization, and staging. Besides 18F-FDG, which may be used in the management and follow-up of endocrine tumors, new tracers have emerged, such as 18F-DOPA for neuroendocrine tumors (NETs) (medullary thyroid carcinoma, pheochromocytomas and paragangliomas and well-differentiated NETs originating from the midgut) and 18F-Choline in the field of primary hyperparathyroidism. Moreover, some peptides such as somatostatin analogs can also be used for peptide receptor radionuclide therapy. In this context, Gallium-68 labeled somatostatin analogs (68Ga-SSA) can help to tailor therapeutic choices and follow the response to treatment in the so-called " theranostic" approach. This review emphasizes the usefulness of these three novel PET tracers (18F-Choline, 18F-FDOPA, and 68Ga-SSA) for primary hyperparathyroidism and neuroendocrine tumors.
|
Authors | Sébastien Bergeret, Judith Charbit, Catherine Ansquer, Géraldine Bera, Philippe Chanson, Charlotte Lussey-Lepoutre |
Journal | Endocrine
(Endocrine)
Vol. 64
Issue 1
Pg. 14-30
(04 2019)
ISSN: 1559-0100 [Electronic] United States |
PMID | 30875057
(Publication Type: Journal Article, Review)
|
Chemical References |
- Gallium Radioisotopes
- Radiopharmaceuticals
- Fluorodeoxyglucose F18
- fluorodopa F 18
- Dihydroxyphenylalanine
- Gallium-68
|
Topics |
- Dihydroxyphenylalanine
(analogs & derivatives)
- Endocrine System Diseases
(diagnostic imaging)
- Fluorodeoxyglucose F18
- Gallium Radioisotopes
- Humans
- Neuroendocrine Tumors
(diagnostic imaging)
- Positron-Emission Tomography
- Radiopharmaceuticals
|